Aktis Oncology, Inc. (AKTS)

Aktis Oncology Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	180.25	37.16	29.51
Short-Term Investments	65.97	260.01	68.35
Cash & Cash Equivalents	246.22	297.17	97.86
Cash Growth	-	203.66%	-
Other Current Assets	3.2	3.69	2.34
Total Current Assets	249.42	300.85	100.2
Property, Plant & Equipment	-	7.3	5.51
Goodwill and Intangibles	-	13.57	15.41
Other Long-Term Assets	-	4.46	1.23
Total Long-Term Assets	-	25.33	22.15
Total Assets	-	326.18	122.36
Accounts Payable	-	1.92	0.96
Deferred Revenue	-	9.28	-
Current Debt	-	1.3	1.53
Other Current Liabilities	26.91	6.33	3.75
Total Current Liabilities	26.91	18.82	6.24
Long-Term Debt	-	10.71	11.87
Other Long-Term Liabilities	-	51.04	0.5
Total Long-Term Liabilities	-	61.75	12.37
Total Liabilities	-	80.58	18.61
Total Debt	11.87	12.01	13.4
Debt Growth	-	-10.39%	-
Retained Earnings	-	-92.83	-48.85
Comprehensive Income	-	0.12	0.08
Shareholders' Equity	-132.39	-87.8	-46.31
Net Cash (Debt)	234.36	285.16	84.46
Net Cash (Debt) Growth	-	237.63%	-
Working Capital	222.51	282.03	93.97

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).